Biopharma | January 07, 2026
Medera doses final patient in high-dose HFpEF gene therapy trial
Heart failure affects an estimated 64.3 million people worldwide
Heart failure affects an estimated 64.3 million people worldwide
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Subscribe To Our Newsletter & Stay Updated
